Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe aisbl (MPE)

YEAR: 2025

MPE Industry[1] related income[2]		
Name of company/ funder	**Amount of income**	**% of overall organisation's income**
Abbvie	2.000 €	0,2%
Alexion	29.468 €	2,8%
Amgen	30.000 €	2,8%
BeOne Medicines	35.000 €	3,3%
Bristol Myers Squibb	62.381 €	5,9%
GlaxoSmithKline	166.549 €	15,8%
Johnson & Johnson	112.718 €	10,7%
Menarini Stemline	30.600 €	2,9%
Oncopeptides	5.000 €	0,5%
Pfizer	122.635 €	11,6%
Prothena	25.000 €	2,4%
Regeneron	68.750 €	6,5%
Roche	1.500 €	0,1%

[1] Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.
[2] This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Sanofi	124.970 €	11,8%
Takeda	58.015 €	5,5%
Subtotal:	**874.586 €**	**82,8%**

MPE Non-industry related income – Public Funding		
Source of funding[3]	**Amount of income**	**% of overall organisation's income**
HE ASCERTAIN	53.736 €	5,1%
HE CERTAINTY	13.446 €	1,3%
IMI SISAQoL	50.244 €	4,8%
ROR2	6.000 €	0,6%
T2Evolve	1.000 €	0,1%
Subtotal:	**124.425 €**	**11,8%**

[3] E.g. membership fees, donations.

MPE Non-industry related income		
Medscape	46.748 €	4,4%
EPAI gUG	3.773 €	0,4%
Other Non-Industry (various)	7.165 €	0,7%
Subtotal:	57.687 €	5,5%
TOTAL[4]:	**1.056.698 €**	**100,0%**

Information required to be included on organisation's website	Please include links below:
• Funding sources:	https://www.mpeurope.org/about-mpe/funding-sources/
• Overall proportion of industry and non-industry:	Industry: 82,8%; Non-Industry incl. Public Funding: 17,2%
• Percentage of the highest contribution from a single company:	15,8% of overall organizations income

[4] In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf